Return to content in this issue

Drug hypersensitivity in cutaneous manifestations of SARS-CoV-2 infected patients

Solano-Solares E¹*, Chica-Guzmán V¹*, Pérez-Allegue I¹, Cabrera-Hernández R¹, Fernández-Guarino M², Fernández-Nieto D², Moreno-García-del-Real C³, de-Andres-Martin A⁴, García-Bermejo L⁵, González-de-Olano D^1,6**, de-la-Hoz-Caballer B^1,6**

¹Allergology Department, Hospital Universitario Ramón y Cajal, IRYCS, Madrid, Spain.
²Dermatology Department Hospital Universitario Ramón y Cajal, IRYCS, Madrid, Spain.
³Pathological Anatomy Department Hospital Universitario Ramón y Cajal, IRYCS, Madrid, Spain.
⁴Immunology Department Hospital Universitario Ramón y Cajal, IRYCS, Madrid, Spain.
⁵Biomarkers and Therapeutic Targets Group, RedinRen, Hospital Universitario Ramón y Cajal, IRYCS, Madrid, Spain.
⁶Spanish Thematic Network and Co-operative Research Centres, ARADyAL, Spain.
*Both authors have equally contributed and should be both considered as first authors
**Both authors should be considered as senior authors.

J Investig Allergol Clin Immunol 2022; Vol. 32(3)
doi: 10.18176/jiaci.0744

• Abstract
• Supplemental Materials

Key words: Cutaneous Manifestations, Drug Provocation T test, First Wave, SARS-CoV-2, Drug Hypersensitivity

	Title	Type	Size
	doi10.18176_jiaci.0744materialsuppltable.pdf	pdf	559.18 Kb
	doi10.18176_jiaci.0744materialsupplfigure.pdf	pdf	243.20 Kb